Boston Scientific shares fall despite positive trial results for WATCHMAN FLX and EKOS devices.

Boston Scientific's shares dropped over 9% despite positive clinical trial results for its WATCHMAN FLX device and EKOS Endovascular System. The CHAMPION-AF trial showed WATCHMAN FLX significantly reduced bleeding risk compared to blood thinners while maintaining similar efficacy for stroke prevention in atrial fibrillation patients. Meanwhile, the HI-PEITHO trial demonstrated the EKOS system plus anticoagulation was superior to anticoagulation alone in reducing pulmonary embolism complications. Analysts remain mixed, with some downgrades and price target cuts, even as the stock hits a 52-week low. The company will continue to monitor patient outcomes over the next five years.